Isis touts positive cholesterol data in LDL study

Shares of Isis Pharmaceuticals were on the rise in early trading on newly released data demonstrating positive results from a small mid-stage trial of ISIS 301012 for bad cholesterol. Researchers in New Orleans reported that high cholesterol patients receiving 400 mgs of the therapy for 10 weeks had an average 70 percent reduction of LDL. All eight patients in the study demonstrated optimal levels of LDL following treatment.

"I can't overemphasize the importance of these results," said Evan Stein, M.D., Ph.D., director of the Metabolic and Atherosclerosis Research Center. "ISIS 301012 produced much more dramatic lipid-lowering effects in these patients than we have ever seen with any other therapeutic agent, including statins and MTP inhibitors. That it did so in patients who were already on maximal lipid-lowering therapies, and did so with such excellent tolerability, is truly remarkable."

- see the release from Isis for more
- read the AP report on the data

Related Articles:
Mid-stage cholesterol data sends Isis stock soaring. Report
Isis to sell $75M in stock. Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.